Genomic Valley Biotech (BOM:539206) Cyclically Adjusted Revenue per Share: ₹3.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539206 Genomic Valley Biotech Ltd BOM:539206
53 GF Score
Price ₹30.00
GF Value ₹11.28
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Genomic Valley Biotech Cyclically Adjusted Revenue per Share?

Genomic Valley Biotech BOM:539206 53 Cyclically Adjusted Revenue per Share is ₹3.03 as of Jun. 2026. GuruFocus rates BOM:539206 with a GF Score™ of 53/100 and a GF Value™ of ₹11.28 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genomic Valley Biotech's adjusted revenue per share for the three months ended in Jun. 2026 was ₹0.130. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹3.03 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genomic Valley Biotech's average Cyclically Adjusted Revenue Growth Rate was 2.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-31), Genomic Valley Biotech's current stock price is ₹30.00. Genomic Valley Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹3.03. Genomic Valley Biotech's Cyclically Adjusted PS Ratio of today is 9.90.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Genomic Valley Biotech was 37.63. The lowest was 7.46. And the median was 15.25.


Genomic Valley Biotech  (BOM:539206) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genomic Valley Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.00/3.03
=9.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Genomic Valley Biotech was 37.63. The lowest was 7.46. And the median was 15.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genomic Valley Biotech Cyclically Adjusted Revenue per Share Related Terms


Genomic Valley Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genomic Valley Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomic Valley Biotech Cyclically Adjusted Revenue per Share Chart

Genomic Valley Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 2.89 3.04

Genomic Valley Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.95 3.01 3.03 3.04 3.03

BOM:539206 vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Genomic Valley Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Valley Biotech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genomic Valley Biotech's Cyclically Adjusted PS Ratio falls into.


BOM:539206
53GF Score
Genomic Valley Biotech Ltd BOM:539206
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomic Valley Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genomic Valley Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.13/167.3573*167.3573
=0.130

Current CPI (Jun. 2026) = 167.3573.

Genomic Valley Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.310 105.961 0.490
201612 0.255 105.196 0.406
201703 0.426 105.196 0.678
201706 0.479 107.109 0.748
201709 0.405 109.021 0.622
201712 0.422 109.404 0.646
201803 0.651 109.786 0.992
201806 0.644 111.317 0.968
201809 0.595 115.142 0.865
201812 0.841 115.142 1.222
201903 1.003 118.202 1.420
201906 0.672 120.880 0.930
201909 0.574 123.175 0.780
201912 0.582 126.235 0.772
202003 1.008 124.705 1.353
202006 0.090 127.000 0.119
202009 0.229 130.118 0.295
202012 0.269 130.889 0.344
202103 0.073 131.771 0.093
202106 0.056 134.084 0.070
202109 0.096 135.847 0.118
202112 0.091 138.161 0.110
202203 0.000 138.822 0.000
202206 3.376 142.347 3.969
202209 0.067 144.661 0.078
202212 2.197 145.763 2.522
202303 3.245 146.865 3.698
202306 0.197 150.280 0.219
202309 0.233 151.492 0.257
202312 0.125 152.924 0.137
202403 0.000 153.035 0.000
202406 0.511 155.789 0.549
202409 0.667 157.882 0.707
202412 0.722 158.323 0.763
202503 0.852 157.552 0.905
202506 0.292 159.755 0.306
202509 0.272 162.289 0.280
202512 0.143 163.281 0.147
202603 0.123 164.272 0.125
202606 0.130 167.357 0.130

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹3.03 mean?
Genomic Valley Biotech (BOM:539206) has a Cyclically Adjusted Revenue per Share of ₹3.03 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomic Valley Biotech and its competitors.
Is Genomic Valley Biotech's Cyclically Adjusted Revenue per Share too high?
Genomic Valley Biotech's current Cyclically Adjusted Revenue per Share is ₹3.03. Overall, Genomic Valley Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Genomic Valley Biotech's Cyclically Adjusted Revenue per Share of ₹3.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomic Valley Biotech and its competitors. Genomic Valley Biotech's current Cyclically Adjusted Revenue per Share is ₹3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.28, compared to a current price of ₹30.00 — trading 166% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹3.03. Genomic Valley Biotech's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Cyclically Adjusted Revenue per Share is ₹3.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?

Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued. The current stock price of ₹30.00 is trading 166% above its estimated GF Value™ of ₹11.28. GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.

Key valuation signals for BOM:539206:

  • Cyclically Adjusted Revenue per Share: ₹3.03
  • GF Value™: ₹11.28 vs. price of ₹30.00 (166% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomic Valley Biotech Business Description

Address 4 K.M. Stone, Berri Charra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Village Kherka Musalman, Jhajjar, HR, IND, 124507
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
53GF Score

Get the complete analysis for BOM:539206

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹30.00
Price
₹11.28
GF Value